PUBLISHER: BIS Research | PRODUCT CODE: 1266586
PUBLISHER: BIS Research | PRODUCT CODE: 1266586
Global Cell-Based Assay Market - A Global and Regional Analysis: Focus on Product, Services, Application, End User, Technology, Regional Analysis, and Competitive Landscape - Analysis and Forecast, 2023-2032
“Global Cell-Based Assay Market to Reach $38.23 Billion by 2032.”
Industry Overview
The global cell-based assay market is expected to reach $38.23 billion in 2032 from $17.20 billion in 2022, at a CAGR of 8.44% during the forecast period 2023-2032.
Market Lifecycle Stage
The global cell-based assay market is anticipated to witness growth during the forecast year 2023-2032, largely fuelled by the promise of a novel breakthrough in the cell-based assay market, which is no longer restricted to drug discovery. The foremost advantage of utilizing cell-based assays is apparent: unlike basic biochemical assays, they provide a more comprehensive representation of biological systems as they encompass not just an isolated receptor or enzyme but all the organelles of a cell functioning as a single entity.
Impact
The impact analysis for the factors that significantly affect the market, namely, drivers, restraints, and opportunities, has been evaluated on a short-term and long-term basis. The short-term assessment considers the period between 2022 and 2026, and the long-term assessment considers the period between 2027 and 2032. Key developments and strategies that have been undertaken by some of the key players in this market have been accounted for evaluation of the impact analysis. Further, these key developments have been assessed to understand the future scope of integrating advancing technologies to enable superior outcomes.
Impact of COVID-19
The cell-based assay market has also been impacted by the pandemic. As per World Health Organization (WHO), COVID-19 has affected millions of people, resulting in a considerable number of deaths. In response, companies have intensified their research and development efforts to create vaccines and treatments for the SARS-CoV-2 virus. This research is considered critical and has remained unaffected, with operations and output continuing as before. As a result of the increase in research activities, the availability of research funding and demand for cell-based test products are expected to expand.
Companies in the industry are adapting their long-and short-term growth strategies to capitalize on opportunities in the research market by introducing innovative products to combat the pandemic. The need for COVID-19 research has created a broad scope for cell-based tests in viral infection research, vaccine development, and drug discovery.
Various COVID-19 vaccines and antiviral medications have been authorized or are under development, and patients are being treated symptomatically. The functional efficiency of the antibodies produced to neutralize the virus is assessed using cell-based assays for both vaccines and treatments. In order to reduce time and increase throughput, cell-based assays are utilized. As a result, the demand for cell-based assays to provide early indications of symptoms in patients has increased. Consequently, the overall impact of COVID-19 on the cell-based assay market is predicted to be positive.
Market Segmentation:
Global Cell-Based Assay Market
Segmentation 1: by Product
- Consumables
- Instruments and Software
- Services
Based on product type, the global cell-based assay market is segmented into consumables, instruments and software, and services.
Segmentation 2: by Region
- North America
- Europe
- Asia-Pacific
- Rest-of-the-World
In 2022, the North America region dominated the global cell-based assay market, and it is expected to hold its dominance throughout the forecast period 2023-2032.
Segmentation 3: by Application
- Drug Screening
- Basic Research
- Predictive Toxicology
- Other Applications (Other Industries, Cell and Gene therapy, among others)
As of 2022, the cell-based assay market (by application) was dominated by drug screening applications, holding a 41.27% market share.
Segmentation 4: by Technology
- Flow Cytometry
- Automated Handling
- High Throughput Screening
- High Content Screening
- Other Technologies (Label-Free Detection, Image Cytometry, among others)
As of 2022, the global cell-based assay market (by technology) was dominated by flow cytometry, holding a 34.11% market share.
Segmentation 5: by End User
- Pharmaceutical and Biopharmaceutical Companies
- Contract Research Organizations (CROs)
- Academic and Research Institutes
- Other End Users (Government Organizations)
As of 2022, the global cell-based assay market (by end user) was dominated by the pharmaceutical and biopharmaceutical companies' segment, holding a 51.36% market share.
Segmentation 6: by Company
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- Corning Incorporated
- Lonza Group AG
- Agilent Technologies, Inc.
- Promega Corporation
- PerkinElmer, Inc.
- Eurofins DiscoverX Products
- Cell Signaling Technology, Inc.
- Charles River Laboratories International, Inc.
- Laboratory Corporation of America Holdings
Based on company, the global cell-based assay market is dominated by Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, among others.
Recent Developments in the Global Cell-Based Assay Market
- In April 2022, Lonza Group AG announced an enhancement to its automated cell therapy manufacturing system called the Cocoon Platform. The latest addition, known as magnetic selection, broadens the platform's capabilities by enabling cell binding, separation, and bead removal (if needed), all conducted through the Cocoon cassette.
- In April 2020, Bio-Rad Laboratories, Inc. completed the acquisition of Celsee, Inc., a company that provides instruments and consumables that enable the isolation, detection, and analysis of individual cells.
- In July 2021, PerkinElmer, Inc. announced that it had reached a definitive agreement to acquire BioLegend, a manufacturer of high-quality antibodies and reagents used in biomedical research, for $5.25 billion.
- In April 2021, Lonza Group AG and Junshi Biosciences announced an expansion of their collaboration aimed at developing and manufacturing biologics. Lonza Group AG would utilize its worldwide network and local operational expertise to help Junshi Biosciences speed up the development of drugs in its pipeline and increase their adoption in the global market. According to the agreement, Lonza Group AG would provide comprehensive assistance, including cell line creation and development, the supply of cell culture media and reagents, process development, and GMP manufacturing.
- In July 2021, Lonza Group AG and CN Bio established a distribution agreement that involves Lonza Group AG providing hepatic cells to CN Bio for prequalification, which would be utilized in their PhysioMimix single-and multi-organ MPS technology. This collaboration aims to revolutionize the generation of preclinical data that is relevant to humans. By using prequalified cells, customers can avoid the need to experiment with multiple cell types, thereby saving time and ensuring the discovery of cells that will grow and function effectively in 3D culture.
Demand - Drivers and Limitations
The following are the demand drivers for the global cell-based assay market:
- Increase in Demand for Cell-Based Assay in Drug Discovery and Development
- Rise in Life Sciences Research Investments
- Technological Advancements
The market is expected to face some limitations due to the following challenges:
- High Cost
- Lack of Standardization
How can this report add value to an organization?
Workflow/Innovation Strategy: The global cell-based assay market is segmented (by product) into three categories, i.e., consumables, instruments and software, and services. The consumables segment is further classified as reagents, assay kits, microplates, cell lines, probes and labels, and other consumables.
Reagents accounted for 29.43% of the share in the global cell-based assay market from 2022 to 2032.
Growth/Marketing Strategy: The global cell-based assay market is anticipated to witness growth during the forecast year 2023-2032. The advent of CRISPR/Cas9 technology has completely transformed gene studies and their functions by offering highly precise and user-friendly genome editing capabilities. CRISPR significantly streamlines the development of more intricate disease-related cell-based assays, enabling researchers to tackle complex questions and study heterogeneous diseases with more relevant and sophisticated assays.
Competitive Strategy: Key players in the global cell-based assay market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global cell-based assay market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Table of Contents
1 Definition
- 1.1 Inclusion and Exclusion Criteria
2 Research Scope
- 2.1 Target Audience
- 2.2 Key Questions Answered in the Report:
3 Research Methodology
- 3.1 Global Cell-Based Assay Market: Research Methodology
- 3.2 Primary Data Sources
- 3.3 Secondary Data Sources
- 3.4 Market Estimation Model
- 3.5 Criteria for Company Profiling
4 Markets Overview
- 4.1 Market Introduction
- 4.1.1 Types of Cell-Based Assays
- 4.2 Current and Future State of Cell-Based Assays in Industries
- 4.3 Emerging Technologies and Applications in the Global Cell-Based Assay Market
- 4.4 Current Market Size and Growth Potential, $Billion, 2022-2032
- 4.5 COVID-19 Impact on Global Cell-Based Assay Market
- 4.5.1 Impact on Cell-Based Assay Companies
5 Industry Insights
- 5.1 Overview
- 5.2 Legal Requirements and Frameworks in the U.S.
- 5.3 Legal Requirements and Frameworks in Europe
- 5.4 Legal Requirements and Frameworks in Asia-Pacific
- 5.4.1 Legal Requirements and Frameworks in Japan
6 Market Dynamics
- 6.1 Overview
- 6.2 Impact Analysis
- 6.2.1 Market Drivers
- 6.2.1.1 Increase in Demand for Cell-Based Assay in Drug Discovery and Development
- 6.2.1.2 Rise in Life Sciences Research Investments
- 6.2.1.3 Technological Advancements
- 6.2.2 Market Restraints
- 6.2.2.1 High Cost
- 6.2.2.2 Lack of Standardization
- 6.2.3 Market Opportunities
- 6.2.3.1 Increased Focus on Regenerative Medicine
- 6.2.3.2 Emergence of Novel Gene Editing Technologies
- 6.2.1 Market Drivers
7 Competitive Landscape
- 7.1 Competitive Landscape Overview
- 7.1.1 Key Developments
- 7.1.2 Product Launch and Expansion Activities
- 7.1.3 Merger and Acquisition Activities
- 7.1.4 Synergistic Activities
- 7.1.5 License and Agreement Activities
- 7.2 Market Share Analysis (2022)
- 7.3 Growth-Share Analysis (2021-2022)
- 7.3.1 Growth-Share Analysis (by Company)
8 Global Cell-Based Assay Market (by Product),$Billion, 2022-2032
- 8.1 Overview
- 8.2 Consumables
- 8.2.1 Reagents
- 8.2.2 Assay Kits
- 8.2.3 Microplates
- 8.2.4 Cell Lines
- 8.2.5 Probes and Labels
- 8.2.6 Other Consumables
- 8.3 Instruments and Software
- 8.4 Services
9 Global Cell-Based Assay Market (by Application), $Billion, 2022-2032
- 9.1 Overview
- 9.1.1 Drug Screening
- 9.1.2 Basic Research
- 9.1.3 Predictive Toxicology
- 9.1.4 Other Applications (Other Industries, Cell and Gene Therapy, and Others)
10 Global Cell-Based Assay Market (by End User), $Billion, 2022-2032
- 10.1 Overview
- 10.2 Pharmaceutical and Biopharmaceutical Companies
- 10.3 Contract Research Organizations (CROs)
- 10.4 Academic and Research Institutes
- 10.5 Other End Users (Government Organizations)
11 Global Cell-Based Assay Market (by Technology), $Billion, 2022-2032
- 11.1 Overview
- 11.2 Flow Cytometry
- 11.3 Automated Handling
- 11.4 High-Throughput Screening
- 11.5 High-Content Screening
- 11.6 Other Technologies (Label-Free Detection, Image Cytometry, and Others)
12 Global Cell-Based Assay Market (by Region), $Billion, 2022-2032
- 12.1 Overview
- 12.2 North America
- 12.2.1 U.S.
- 12.2.2 Canada
- 12.3 Europe
- 12.3.1 Germany
- 12.3.2 U.K.
- 12.3.3 France
- 12.3.4 Italy
- 12.3.5 Spain
- 12.3.6 Rest-of-Europe
- 12.4 Asia-Pacific
- 12.4.1 China
- 12.4.2 Japan
- 12.4.3 India
- 12.4.4 South Korea
- 12.4.5 Australia
- 12.4.6 Rest-of-Asia-Pacific
- 12.5 Rest-of-the-World
13 Company Profiles
- 13.1 Overview
- 13.1.1 Becton, Dickinson and Company
- 13.1.1.1 Company Overview
- 13.1.1.2 Role of Becton, Dickinson and Company in the Global Cell-Based Assay Market
- 13.1.1.3 Major Product: Key Specifications
- 13.1.1.4 Customers and Competitions
- 13.1.1.4.1 Key Customers
- 13.1.1.4.2 Key Competitors
- 13.1.1.5 Analyst Perspective
- 13.1.2 Bio-Rad Laboratories, Inc.
- 13.1.2.1 Company Overview
- 13.1.2.2 Role of Bio-Rad Laboratories, Inc. in the Global Cell-Based Assay Market
- 13.1.2.3 Major Product: Key Specifications
- 13.1.2.4 Customers and Competitions
- 13.1.2.4.1 Key Customers
- 13.1.2.4.2 Key Competitors
- 13.1.2.5 Analyst Perspective
- 13.1.3 Danaher Corporation
- 13.1.3.1 Company Overview
- 13.1.3.2 Role of Danaher Corporation in the Global Cell-Based Assay Market
- 13.1.3.3 Major Product: Key Specifications
- 13.1.3.4 Customers and Competitions
- 13.1.3.4.1 Key Customers
- 13.1.3.4.2 Key Competitors
- 13.1.3.5 Analyst Perspective
- 13.1.4 Merck KGaA
- 13.1.4.1 Company Overview
- 13.1.4.2 Role of Merck KGaA in the Global Cell-Based Assay Market
- 13.1.4.3 Major Product: Key Specifications
- 13.1.4.4 Key Competitors
- 13.1.4.5 Analyst Perspective
- 13.1.5 Thermo Fisher Scientific, Inc.
- 13.1.5.1 Company Overview
- 13.1.5.2 Role of Thermo Fisher Scientific, Inc. in the Global Cell-Based Assay Market
- 13.1.5.3 Major Product: Key Specifications
- 13.1.5.4 Key Competitors
- 13.1.5.5 Analyst Perspective
- 13.1.6 Corning Incorporated
- 13.1.6.1 Company Overview
- 13.1.6.2 Role of Corning Incorporated in the Global Cell-Based Assay Market
- 13.1.6.3 Major Product: Key Specifications
- 13.1.6.4 Key Competitors
- 13.1.6.5 Analyst Perspective
- 13.1.7 Lonza Group AG
- 13.1.7.1 Company Overview
- 13.1.7.2 Role of Lonza Group AG in the Global Cell-Based Assay Market
- 13.1.7.3 Major Product: Key Specifications
- 13.1.7.4 Key Competitors
- 13.1.7.5 Analyst Perspective
- 13.1.8 Agilent Technologies, Inc.
- 13.1.8.1 Company Overview
- 13.1.8.2 Role of Agilent Technologies, Inc. in the Global Cell-Based Assay Market
- 13.1.8.3 Major Product: Key Specifications
- 13.1.8.4 Customers and Competitions
- 13.1.8.4.1 Key Customers
- 13.1.8.4.2 Key Competitors
- 13.1.8.5 Analyst Perspective
- 13.1.9 Promega Corporation
- 13.1.9.1 Company Overview
- 13.1.9.2 Role of Promega Corporation in the Global Cell-Based Assay Market
- 13.1.9.3 Major Product: Key Specifications
- 13.1.9.4 Customers and Competitions
- 13.1.9.4.1 Key Customers
- 13.1.9.4.2 Key Competitors
- 13.1.9.5 Analyst Perspective
- 13.1.10 PerkinElmer, Inc.
- 13.1.10.1 Company Overview
- 13.1.10.2 Role of PerkinElmer Inc. in the Global Cell-Based Assay Market
- 13.1.10.3 Major Product: Key Specifications
- 13.1.10.4 Key Competitors
- 13.1.10.5 Analyst Perspective
- 13.1.11 Eurofins DiscoverX Products
- 13.1.11.1 Company Overview
- 13.1.11.2 Role of Eurofins DiscoverX Products in the Global Cell-Based Assay Market
- 13.1.11.3 Major Product: Key Specifications
- 13.1.11.4 Key Competitors
- 13.1.11.5 Analyst Perspective
- 13.1.12 Cell Signaling Technology, Inc.
- 13.1.12.1 Company Overview
- 13.1.12.2 Role of Cell Signaling Technology, Inc. in the Global Cell-Based Assay Market
- 13.1.12.3 Major Product: Key Specifications
- 13.1.12.4 Key Competitors
- 13.1.12.5 Analyst Perspective
- 13.1.13 Charles River Laboratories International, Inc.
- 13.1.13.1 Company Overview
- 13.1.13.2 Role of Charles River Laboratories International, Inc. in the Global Cell-Based Assay Market
- 13.1.13.3 Major Product: Key Specifications
- 13.1.13.4 Key Competitors
- 13.1.13.5 Analyst Perspective
- 13.1.14 Laboratory Corporation of America Holdings
- 13.1.14.1 Company Overview
- 13.1.14.2 Role of Laboratory Corporation of America Holdings in Global Cell-Based Assay Market
- 13.1.14.3 Major Product: Key Specifications
- 13.1.14.4 Key Competitors
- 13.1.14.5 Analyst's Perspective
- 13.1.1 Becton, Dickinson and Company
List of Figures
- Figure 1: Impact Analysis of Drivers, Challenges, and Opportunities on the Global Cell-Based Assay Market
- Figure 2: Global Cell-Based Assay Market (by Product), $Billion, 2022-2032
- Figure 3: Global Cell-Based Assay Market (by End User), $Billion, 2022 and 2032
- Figure 4: Global Cell-Based Assay Market (by Region), 2022
- Figure 5: Global Cell-Based Assay Market Regional Segmentation
- Figure 6: Global Cell-based Assay Market Methodology
- Figure 7: Primary Research Methodology
- Figure 8: Top-Down Approach (Segment-Wise Analysis)
- Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 10: Cellular Processes Utilized to Investigate the Impacts in Cell-Based Assays
- Figure 11: Emerging Technologies in the Global Cell-Based Assay Market
- Figure 12: Global Cell-Based Assay Market, $Billion, 2022-2032
- Figure 13: Impact of COVID-19 on Cell-Based Assay Companies
- Figure 14: Global Cell-Based Assay Market - Market Dynamics
- Figure 15: Total U.S. Life Sciences Venture Capital Funding, $Billion, 2016-2021
- Figure 16: Uses of Cell-based Assays in Regenerative Medicine
- Figure 17: Share of Key Developments and Strategies, January 2020 to March 2023
- Figure 18: Share of Product Launch and Expansion Activities (by Company), January 2020 to March 2023
- Figure 19: Share of Merger and Acquisition Activities (by Company), January 2020 to March 2023
- Figure 20: Share of Synergistic Activities (by Company), January 2020 to March 2023
- Figure 21: Market Share Analysis for Global Cell-Based Assay Market, 2022
- Figure 22: Growth-Share Analysis for Global Cell-Based Assay Market (by Company), 2021-2022
- Figure 23: Global Cell-Based Assay Market (by Product), $Billion, 2022-2032
- Figure 24: Global Cell-Based Assay Market (Consumables), $Billion, 2022-2032
- Figure 25: Global Cell-Based Assay Market (Reagents), $Billion, 2022-2032
- Figure 26: Global Cell-Based Assay Market (Assay Kits), $Billion, 2022-2032
- Figure 27: Global Cell-Based Assay Market (Microplates), $Billion, 2022-2032
- Figure 28: Global Cell-Based Assay Market (Cell Lines), $Billion, 2022-2032
- Figure 29: Global Cell-Based Assay Market (Probes and Labels), $Billion, 2022-2032
- Figure 30: Global Cell-Based Assay Market (Other Consumables), $Billion, 2022-2032
- Figure 31: Global Cell-Based Assay Market (Instruments and Software), $Billion, 2022-2032
- Figure 32: Global Cell-Based Assay Market (Services), $Billion, 2022-2032
- Figure 33: Global Cell-Based Assay Market (by Application)
- Figure 34: Global Cell-Based Assay Market (by Application), $Billion, 2022 and 2032
- Figure 35: Global Cell-Based Assay Market (Drug Screening), $Billion, 2022-2032
- Figure 36: Global Cell-Based Assay Market (Basic Research), $Billion, 2022-2032
- Figure 37: Global Cell-Based Assay Market (Predictive Toxicology), $Billion, 2022-2032
- Figure 38: Global Cell-Based Assay Market (Other Applications), $Billion, 2022-2032
- Figure 39: Global Cell-Based Assay Market (by End User)
- Figure 40: Global Cell-Based Assay Market (by End User), $Billion, 2022 and 2032
- Figure 41: Global Cell-Based Assay Market (Pharmaceutical and Biopharmaceutical Companies), $Billion, 2022-2032
- Figure 42: Global Cell-Based Assay Market (Contract Research Organizations (CROs)), $Billion, 2022-2032
- Figure 43: Global Cell-Based Assay Market (Academic and Research Institutes), $Billion, 2022-2032
- Figure 44: Global Cell-Based Assay Market (Other End Users (Government Organizations), $Billion, 2022-2032
- Figure 45: Global Cell-Based Assay Market (by Technology)
- Figure 46: Global Cell-Based Assay Market (by Technology), $Billion, 2022 and 2032
- Figure 47: Global Cell-Based Assay Market (Flow Cytometry), $Billion, 2022-2032
- Figure 48: Global Cell-Based Assay Market (Automated Handling), $Billion, 2022-2032
- Figure 49: Global Cell-Based Assay Market (High-Throughput Screening), $Billion, 2022-2032
- Figure 50: Global Cell-Based Assay Market (High-Content Screening), $Billion, 2022-2032
- Figure 51: Global Cell-Based Assay Market (Other Technologies), $Billion, 2022-2032
- Figure 52: Global Cell-Based Assay Market Snapshot (by Region)
- Figure 53: Global Cell-Based Assay Market (by Region), $Billion, 2022-2032
- Figure 54: North America Cell-Based Assay Market, $Billion, 2022-2032
- Figure 55: North America: Market Dynamics
- Figure 56: North America Cell-Based Assay Market (by Country), $Billion, 2022-2032
- Figure 57: U.S. Cell-Based Assay Market, $Billion, 2022-2032
- Figure 58: Canada Cell-Based Assay Market, $Billion, 2022-2032
- Figure 59: Europe Cell-Based Assay Market, $Billion, 2022-2032
- Figure 60: Europe: Market Dynamics
- Figure 61: Europe Cell-Based Assay Market (by Country), $Billion, 2022-2032
- Figure 62: Germany Cell-Based Assay Market, $Billion, 2022-2032
- Figure 63: U.K. Cell-Based Assay Market, $Billion, 2022-2032
- Figure 64: France Cell-Based Assay Market, $Billion, 2022-2032
- Figure 65: Italy Cell-Based Assay Market, $Billion, 2022-2032
- Figure 66: Spain Cell-Based Assay Market, $Billion, 2022-2032
- Figure 67: Rest-of-Europe Cell-Based Assay Market, $Billion, 2022-2032
- Figure 68: Asia-Pacific Cell-Based Assay Market, $Billion, 2022-2032
- Figure 69: Asia-Pacific: Market Dynamics
- Figure 70: Asia-Pacific Cell-Based Assay Market (by Country), $Billion, 2022-2032
- Figure 71: China Cell-Based Assay Market, $Billion, 2022-2032
- Figure 72: Japan Cell-Based Assay Market, $Billion, 2022-2032
- Figure 73: India Cell-Based Assay Market, $Billion, 2022-2032
- Figure 74: South Korea Cell-Based Assay Market, $Billion, 2022-2032
- Figure 75: Australia Cell-Based Assay Market, $Billion, 2022-2032
- Figure 76: Rest-of-Asia-Pacific Cell-Based Assay Market, $Billion, 2022-2032
- Figure 77: Rest-of-the-World Cell-Based Assay Market, $Billion, 2022-2032
- Figure 78: Total Number of Companies Profiled
- Figure 79: Becton, Dickinson and Company: Product Portfolio
- Figure 80: Bio-Rad Laboratories, Inc.: Product Portfolio
- Figure 81: Danaher Corporation: Product Portfolio
- Figure 82: Merck KGaA: Product Portfolio
- Figure 83: Thermo Fisher Scientific, Inc.: Product Portfolio
- Figure 84: Corning Incorporated: Product Portfolio
- Figure 85: Lonza Group AG: Product Portfolio
- Figure 86: Agilent Technologies, Inc.: Product Portfolio
- Figure 87: Promega Corporation: Product Portfolio
- Figure 88: PerkinElmer Inc.: Product Portfolio
- Figure 89: Eurofins DiscoverX Products: Product Portfolio
- Figure 90: Cell Signaling Technology, Inc.: Product Portfolio
- Figure 91: Charles River Laboratories International, Inc.: Product Portfolio
- Figure 92: Laboratory Corporation of America Holdings.: Product Portfolio
List of Tables
- Table 1: Current and Future State of Cell-Based Assay in Industries
- Table 2: Utilizing the Potential of Cell-Based Assays: Novel Instruments and Methodologies in 2020-2021
